MP25-10 GENOMIC BIOMARKERS OF RESPONSE TO NIVOLUMAB/IPILIMUMAB AND NIVOLUMAB MONOTHERAPY IN 108 PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Renzo G. DiNatale(Memorial Sloan Kettering Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Samuel Murray(Memorial Sloan Kettering Cancer Center), Paul Russo(Memorial Sloan Kettering Cancer Center), Diego Chowell(Icahn School of Medicine at Mount Sinai), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Vladimir Makarov, Timothy A. Chan(Cleveland Clinic), Jonathan Coleman(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Chung‐Han Lee(Memorial Sloan Kettering Cancer Center)
Cited by 0
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k